Welcome to LookChem.com Sign In|Join Free
  • or

191732-72-6

Post Buying Request

191732-72-6 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Factory Lenalidomide in stock CAS No.191732-72-6
Cas No: 191732-72-6
No Data 1 Kilogram 10 Metric Ton/Day Shaanxi WuZhiYuan Biological Technology Co.,Ltd Contact Supplier
Hot sales SGT263 factory stock
Cas No: 191732-72-6
No Data 10 Gram 500 Kilogram/Month Wuhan New-Rise Biochem Co,. Ltd Contact Supplier
Lenalidomide
Cas No: 191732-72-6
No Data 1 Kilogram 500 Kilogram/Month Huarong Industrial Group Ltd. Contact Supplier
Lower price Manufacturer 99% Lenalidomide
Cas No: 191732-72-6
USD $ 100.0-100.0 / Kilogram 1 Kilogram 10 Metric Ton/Month Taizhou Creating Chemical Co.,Ltd Contact Supplier
Lenalidomide
Cas No: 191732-72-6
No Data No Data No Data Nanjing pharmaluxury Co.,Ltd. Contact Supplier
Lenalidomide Manufacturer/High quality/Best price/In stock
Cas No: 191732-72-6
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Factory Lenalidomide in stock CAS No.191732-72-6
Cas No: 191732-72-6
USD $ 1.0-3.0 / Metric Ton 1 Metric Ton 10 Metric Ton/Day Hebei yanxi chemical co.,LTD. Contact Supplier
High purity lenalidomide CAS: 191732-72-6
Cas No: 191732-72-6
USD $ 1.0-5.0 / Kilogram 1 Kilogram 99999 Kilogram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
High quality Lenalidomide supplier in China
Cas No: 191732-72-6
No Data No Data No Data Simagchem Corporation Contact Supplier
Lenalidomide
Cas No: 191732-72-6
USD $ 5.0-10.0 / Kilogram 1 Kilogram 1000 Kilogram/Month Enke Pharma-tech Co.,Ltd. (Cangzhou, China ) Contact Supplier

191732-72-6 Usage

Uses

A Thalidomide analog known to have immunomodulatory properties

Definition

ChEBI: A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha.

Chemical Properties

Yellow Solid

Antitumor Drug

Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.
Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide.
In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM).
On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer.
The above information is edited by the Chemicalbook Geqian.

Uses

Lovastatin content <1% 98%

Uses

Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

Brand name

Revlimid(Celgene).

Uses

Immunomodulatory drug; analog of Thalidomide.
InChI:InChI=1/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

191732-72-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name lenalidomide

1.2 Other means of identification

Product number -
Other names Leflunomidum

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:191732-72-6 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields